Abstracts & Publications

Recent Publications

Date	Location	Title	Details
14 Mar 2023	13th World ADC Conference, London	Novel Target Identification Using Oxford BioTherapeutics' Proprietary Proteomics Target Discovery, OGAP(R), for First-in-Class ADCs and Other Antibody Therapeutics	​View here
14 Mar 2023	13th World ADC Conference, London	Oxford BioTherapeutics and ImmunoGen Partner to Develop Multiple First-in Class Antibody-Drug Conjugates in Cancer Indications with High Unmet Clinical Need	View here
22 Oct 2022	​ Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2022 Sep 27:CCR-22.	A Novel B7-H6-targeted IgG-like T-cell Engaging Antibody for the Treatment of Gastrointestinal Tumors.	​View here
8 - 13 April 2022	AACR Annual Meeting 2022, New Orleans, Louisiana	Potential novel immuno-oncology mechanism revealed during translational Phase I immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient.	View here
8 - 13 April 2022	AACR Annual Meeting 2022, New Orleans, Louisiana	Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results	View here
3 – 7 June 2022	ASCO Annual Meeting 2022, Chicago	​​ Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results	View here

Selected Past Publications

Date	Location	Title	Details
27-28 April 2020	AACR Annual Meeting 2020, Virtual meeting.	Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile	​View here
09 January 2020	Haematologica 2020; Volume 105(11):2584-2591	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models	View here
21 June 2019	Mol Cancer Ther 2019;18:1533–43; AACR	​  MEN1309/OBT076, a First-In-Class Antibody– Drug Conjugate Targeting CD205 in Solid Tumors	View here
14-18 April 2018	​ AACR Annual Meeting 2018, Chicago, Illinois	Preclinical Development of a Novel Antibody-Drug  Conjugate Targeting “Cold” Tumors	View here
14-18 April 2018	AACR Annual Meeting 2018, Chicago, Illinois	​ Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development	View here
1-5 April 2017	AACR Annual Meeting 2017, Washington, D.C., USA ​	Analysis of tumor infiltrating lymphocytes and in vitro exhausted T cell models to identify unique Immuno-Oncology targets	View here
16-20 April 2016	​ AACR Annual Meeting 2016, New Orleans, Louisiana	The use of proteomics to analyse whole tumors and identify unique stroma cell targets for antibody-based therapeutics	View here
18-22 April 2015	​ AACR Annual Meeting 2015, Philadelphia, Pennsylvania	​ The use of proteomics to analyze whole tumors and identify unique immuno-oncology targets for antibody-based therapeutics	View here
5-9 April 2014	​ AACR Annual Meeting 2014, San Diego, CA	Proteomics and Selecting the Right Combination of Target and Toxin for Antibody-Drug-Conjugate (ADC) Development	View here
31 March - 5 April 2012	AACR Annual Meeting 2012, Chicago	​ Proteomics highlights which G-protein coupled receptors are candidates for ADC development	View here